Every dollar on this page comes from Medicare Part D, the drug program for 55 million seniors and disabled adults. The top 20 drugs alone account for 43.8% of all Part D spending. Cash and commercial prices can run several times higher, especially for brand-name drugs with no generic equivalent.
The $212 Billion Picture
The bar below breaks that $212.7 billion across therapeutic categories. Diabetes drugs alone consume 15.3% of the total, the single largest named slice. Blood thinners take another 11.1%, driven almost entirely by Eliquis (apixaban) at 20.2 million Medicare Part D claims.
Notice the mismatch. Diabetes is 15.3% of spend but only 5.2% of claims, because insulins and GLP-1s like Ozempic run over $1,000 per Medicare Part D claim. See section 7 for the full category breakdown.
Two Americas of Prescribing
The 10 most-filled drugs in America are cheap generics. Atorvastatin, Amlodipine, Lisinopril, and Levothyroxine are all under $25 per Medicare Part D claim. The 10 most-expensive-per-claim drugs run $20,000 or more each fill and serve tens of thousands of patients, not tens of millions. Same country, two drug economies.
The Everyday 10
Ten generic drugs, over 300 million fills. Medicare Part D pays under $25 per claim. They keep blood pressure, cholesterol, and thyroid in range for tens of millions of seniors.
The Costly 10
Ten specialty drugs, each $20,000 or more per Medicare Part D claim. Combined they serve roughly 200,000 patients. This is where Medicare's dollars go furthest but reach fewest.
Atorvastatin at $14.69 per claim across 67.6 million claims costs Medicare Part D about $994 million in 2023. Ustekinumab (Stelara) at $26,711.86 per claim across just 73,053 claims costs Part D about $1.95 billion. Generics dominate by volume, specialty drugs dominate by dollars. Both shape the $212.7 billion total; neither is wrong, and both are true at once.
The 80/20 of Part D Spending
The top 20 drugs account for 43.8% of all Medicare Part D spending. The top 100 reach 74.4%. By the top 500, you've covered 96.8% of everything Medicare paid for prescriptions in 2023. The curve rises steeply, then flattens. This is what pharmaceutical economics looks like in real numbers.
The roughly 1,200 drugs in the long tail are low-volume, cheap, or both. They fill out the catalog but barely move the bill. Any serious conversation about Part D costs is really a conversation about the top 100. For the manufacturers behind those drugs, see /pharma-transparency.
What America Treats Most
Hypertension has 106 approved drugs in this dataset. Diabetes has 71. The number of drugs approved for a condition is a rough proxy for how much pharmaceutical R&D has targeted it, and for how many treatment options exist for patients.
Hypertension has so many drugs because it's so common that multiple classes compete for market share. ACE inhibitors, ARBs, beta blockers, calcium channel blockers, and diuretics all treat the same condition from different angles. Rarer diseases often show fewer drugs not because they need fewer, but because drug-development economics concentrate on large patient populations.
Therapeutic Categories
Eighteen therapeutic categories, grouped by body system or disease area. Each card shows the number of drugs tracked and combined Medicare Part D spend.
Diabetes
Diabetes. 13 drugs, 15.3% of Medicare Part D spend, led by Metformin at 31.8 million claims.
Explore Metformin Hcl →Blood Thinners
Blood Thinners. 7 drugs, 11.1% of Medicare Part D spend, led by Eliquis (apixaban) at 20.2 million claims.
Explore Apixaban →Pain & Inflammation
Pain & Inflammation. 17 drugs, 1.6% of Medicare Part D spend, led by Gabapentin at 33.9 million claims.
Explore Gabapentin →Heart & Blood Pressure
Heart & Blood Pressure. 25 drugs, 1.6% of Medicare Part D spend, led by Amlodipine at 46.6 million claims.
Explore Amlodipine Besylate →Mental Health
Mental Health. 19 drugs, 1.6% of Medicare Part D spend, led by Trazodone at 16.3 million claims.
Explore Trazodone Hcl →Cholesterol & Lipids
Cholesterol & Lipids. 9 drugs, 1.4% of Medicare Part D spend, led by Atorvastatin at 67.6 million claims.
Explore Atorvastatin Calcium →Prostate & Urinary
Prostate & Urinary. 8 drugs, 1.4% of Medicare Part D spend, led by Tamsulosin at 18.9 million claims.
Explore Tamsulosin Hcl →Respiratory & Allergy
Respiratory & Allergy. 11 drugs, 1.2% of Medicare Part D spend, led by Albuterol at 17.7 million claims.
Explore Albuterol Sulfate →Stomach & Digestive
Stomach & Digestive. 10 drugs, 0.7% of Medicare Part D spend, led by Omeprazole at 27.2 million claims.
Explore Omeprazole →Eye Care
Eye Care. 6 drugs, 0.6% of Medicare Part D spend, led by Latanoprost at 9.9 million claims.
Explore Latanoprost →Part D Spending by State
The table ranks states by total Medicare Part D spend, but per-capita tells a different story. Michigan leads per capita at $2,134.84. Utah comes in lowest at $557.35. The gap reflects population age, chronic-disease burden, and the share of residents on Medicare. Medicare negotiates drug prices nationally, so unit prices do not vary state to state.
The Diabetes and heart-disease belt shows up clearly in the per-capita ranking. Florida ranks second by total spend but only middle-of-the-pack per capita, because it has a huge retiree population spread across many younger residents. Michigan, Kentucky, and Missouri lead per capita because a larger share of their general population is on Medicare and filling multiple prescriptions.
The Polypharmacy Reality
7.0
7.0 prescriptions per Medicare enrollee per year, on average, counted across the 55 million people on Part D.
Polypharmacy is the quiet reality behind Medicare Part D totals. A senior with hypertension, diabetes, and high cholesterol is already on 4 to 6 drugs before they see a cardiologist. Add heart failure or atrial fibrillation and the count climbs to 8 or 10. This isn't over-prescribing. It's modern chronic-disease care catching up with two decades of guideline updates, with each added drug targeting a specific risk pathway. The tradeoff is real. Every added drug carries a small interaction risk and an adherence cost. For readers managing their own medication lists, /conditions/hypertension, /conditions/diabetes, and /conditions/heart-failure are practical starting points.
The Specialist-Only Drugs
Most Part D drugs are handled by any family or internal-medicine doctor. A small group is written by fewer than a thousand prescribers nationwide — subspecialty teams at academic medical centers, treating rare conditions with drugs that cost tens of thousands per fill.
Atorvastatin has 360,565 prescribers; it's on every internal-medicine formulary in the country. Vutrisiran (Amvuttra) has 11 prescribers and costs Medicare Part D $121,437.68 per claim. Specialty drugs like these are handled by named teams at academic centers, not community primary care. When prescriber count is low and cost-per-claim is high, the drug is almost certainly subspecialty-only.
Complete Drug Rankings
All 1,779 Medicare Part D drugs, ranked by annual prescription count. Top 50 shown below; expand to browse the full list, or click any drug for claim history, state breakdown, and prescribing doctors.
Frequently Asked Questions
How much does the US spend on prescription drugs each year?
Medicare Part D alone paid $212.7 billion for 1.39 billion prescriptions in 2023, covering 55 million seniors and disabled adults. Total US prescription spending across all payers is roughly three times that, once Medicaid, commercial insurance, and cash pay are added. This page tracks the Medicare Part D slice only, because it's the most detailed public dataset.
Why is Medicare data useful for understanding drug costs?
Medicare Part D is the largest single drug payer in the US and releases prescriber-level data every year. It covers 55 million people and 1,779 drugs in 2023. No commercial payer publishes at this level of detail. Part D is not the whole picture, but it's the clearest public window into what America actually fills.
Do commercial or cash prices match Medicare Part D prices?
For generics, they're usually close. Atorvastatin at $14.69 per Medicare Part D claim is roughly what a cash-pay customer would see at a discount pharmacy. For brand-name drugs like Eliquis, Ozempic, or Stelara, commercial and cash prices can run 2 to 5 times the Medicare Part D payment. Medicare negotiates; individual patients paying cash do not have that leverage.
Which drugs are prescribed most often?
Atorvastatin leads at 67.6 million Medicare Part D claims in 2023. The top 10 are all cheap generics: Amlodipine, Levothyroxine, Lisinopril, Gabapentin, Losartan, Metformin, Metoprolol, Omeprazole, and Rosuvastatin. Medicare Part D pays under $25 per claim for each of them.
Which drugs have the highest cost per prescription?
Ustekinumab (Stelara) tops the list at $26,711.86 per Medicare Part D claim. Cabozantinib (Cabometyx), Tafamidis (Vyndamax), Lenvatinib (Lenvima), and Sofosbuvir/Velpatasvir (Epclusa) all exceed $23,000 per claim. These are specialty drugs for autoimmune disease, cancer, rare cardiac amyloidosis, and hepatitis C.
How many drugs does a typical Medicare senior take?
About 7 prescriptions per year on average, across the 55 million people enrolled in Part D. Seniors managing multiple chronic conditions routinely fill 8 to 10. Polypharmacy is the norm, not the exception, once someone has hypertension plus diabetes plus high cholesterol plus one heart condition.
Why does drug spending vary so much between states?
Per-capita Medicare Part D spending ranges from $557.35 in Utah to $2,134.84 in Michigan. The driver is population age structure and chronic-disease burden, not drug prices. Medicare negotiates nationally, so the unit price for a drug is the same everywhere. States with older populations and higher rates of diabetes, heart disease, and hypertension simply fill more prescriptions per person.
Where can I see detailed data for a specific drug?
Each of the 1,779 drugs has its own page at /drugs/[drug-name]. Those pages show year-over-year claim volume, Medicare Part D cost per claim, number of beneficiaries, prescriber count, and how the drug ranks within its therapeutic category.
Methodology & Sources
All figures come from the CMS Medicare Part D Prescriber Public Use File, 2023 calendar year. Claims, beneficiaries, and payments are aggregated from the provider-drug level up to the drug level, one page per drug. We use CMS's generic-name rollup, so all manufacturers of a molecule combine into a single row.
- Source
- CMS Medicare Part D Prescriber Public Use File, 2023 (most recent annual release).
- Limits
- Medicare Part D payments only. Part B infusion drugs administered in clinic are not in this file. Medicaid, commercial insurance, and cash-pay figures are separate datasets and are not aggregated here. Drugs with fewer than 100 claims per year are suppressed by CMS for patient privacy.
- Update cadence
- CMS refreshes the Part D file annually with a roughly 18-month lag; our aggregates regenerate when that happens.
Explore More Healthcare Data
Pharma Transparency →
Which manufacturers are behind the top drugs, and what they paid doctors last year.
Procedure Costs →
Medicare payments and commercial ranges for 128 common procedures.
Conditions →
Over 1,300 conditions with the specialists, symptoms, and drugs that treat them.
State Health Reports →
State-by-state health rankings, county-level chronic disease data, and access gaps.